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Recently we predicted the 3D structure of the human 2-adrener-
gic receptor (2AR) and of the binding site of several agonists and
antagonists to 2AR. These predictions (MembStruk and HierDock)
included no explicit water and only a few lipid molecules. Here we
include explicit H2O and an infinite lipid bilayer membrane in
molecular dynamics (MD) simulations of three systems: apo-2AR,
epinephrine-bound 2AR, and butoxamine-bound 2AR (epineph-
rine is an endogenous agonist, and butoxamine is a 2AR selective
antagonist). The predicted structures for apo-2AR and butoxam-
ine-2AR are stable in MD, but in epinephrine-2AR, extracellular
water trickles into the binding pocket to mediate hydrogen bond-
ing between the catechol of epinephrine and Ser-204 on helix 5.
The epinephrine-2AR structure shows dynamic flexibility with
small, piston-like movements of helices 3 and 6 and transient
interhelical hydrogen bonding between Ser-165 on transmem-
brane 4 and Ser-207 on transmembrane 5. These couplings and
motions may play a role in protein activation. The apo-2AR shows
less dynamic flexibility, whereas the antagonist-2AR structure is
quite rigid. This MD validation of the structure predictions for
G protein-coupled receptors in explicit lipid and water suggests
that these methods can be trusted for studying the mechanism
of activation and the design of subtype-specific agonists and
antagonists.
The nine human adrenergic receptors all respond to endogenousligands epinephrine and norepinephrine. These adrenergic
receptors are G protein-coupled receptors (GPCRs), in which
binding of an agonist in the extracellular region activates a G
protein in the cytoplasm. Three of the nine adrenergic receptors
belong to the -subclass of adrenergic receptors, of which 1AR is
found mostly in the vessels of cardiac and skeletal muscle and
known to cause vasodilation and an increase in cardiac output. The
-blocking drugs were developed to antagonize 1AR for treat-
ment of heart disease. The2-Adrenergic receptor (2AR) protein
is found predominantly in bronchial smooth muscle, causing bron-
chodilation when activated. Antiasthma drugs, such as salbutamol,
act as agonists to 2AR. Thus, current -blocking drugs tend to
antagonize 2AR, causing a bronchioconstriction risk to asthmat-
ics. Similarly, antiasthma agonists for 2AR may interact with
1AR to cause such side effects as increased heart rate and blood
pressure (1). Consequently 2AR has been widely studied resulting
in awide spectrumof pharmacologically well characterized agonists
(activators) and antagonists (inhibitors) (2). However, subtype
selectivity continues to be a serious issue for these and essentially
all other GPCRs.
A major impediment to designing drugs for GPCRs with greater
subtype specificity is the lack of a 3D structure for any human
GPCR. Consequently, we developed the MembStruk computa-
tional method to predict the structure of GPCRs (3, 4), which we
validate by predicting the ligand-binding sites on the predicted
GPCR using the HierDock ligand-docking method (5). These
methods have been applied to several GPCRs (5–9), including the
structure and agonistantagonist binding sites for human2AR(7).
The calculations validating the predicted structure of these ligand–
GPCR complexes involve approximations in the treatment of
solvent and the lipid membrane that are suitable for a minimized
structure but not adequate for describing the dynamics of the
receptorligand complex so relevant to activation by agonists and
efficacy of antagonists (2, 10–14).
In this article we extend the computational model to describe the
ligand–2AR complex by incorporating it into a continuous infinite
lipid bilayer membrane (with periodic boundary conditions) while
including full solvation with water and salt. Then, starting with the
MembStruk–HierDock predicted structures of 2AR with and
without bound ligand, we carried out molecular dynamics (MD)
simulations on these systems for several nanoseconds. This proce-
dure allows us to validate the stability of the predicted structures
and to determine the nature of dynamical effects. We considered
three systems:
Y apo-2AR, the MembStruk-predicted structure of 2AR with
no ligand bound;
Y epinephrine-2AR, the MembStruk–HierDock-predicted struc-
ture of 2AR with the endogenous agonist epinephrine (shown
in Fig. 1) bound, and
Y butoxamine-2AR, the MembStruk–HierDock-predicted struc-
ture of 2AR with the 2-selective antagonist butoxamine
(shown in Fig. 1) bound.
These structures are stable in the MD studies, supporting the
accuracy of the MembStruk and HierDock predictions. However,
there are some important differences between the various MD
simulations. Both apo-2AR and epinephrine-2AR exhibit some-
what flexible dynamic structures, whereas the butoxamine-2AR
structure proves to be rigid and stiff. The MD simulation of
epinephrine-2AR shows that water enters the epinephrine-
binding cavity to mediate the hydrogen bond between the catechol
group of epinephrine and Ser-204 on transmembrane (TM) 5.
We compare these results to experimental results relevant to the
process of coupling agonist binding to G protein activation, which
is believed to involvemotions of several TMhelices. Indeedmotions
of TM3, -5, and -6 have been established to be especially important
(12). Experiments show that binding of the ligand to helices 3 and
5 is fast, whereas the motion of helix 6 to bind noncovalently to the
ligand takes much longer (12). Helix 6 is believed to undergo either
a clockwise rotation to helix 5 or a tilting in the cytoplasmic end
toward helix 5. Piston-like movements of helix 6 into themembrane
have not (yet) been observed. The time scale of these motions are
in the range of nanoseconds (noncovalently binding) to millisec-
Conflict of interest statement: No conflicts declared.
Abbreviations: 2AR, 2-adrenergic receptor; CRMS, RMS deviation in  carbon coordi-
nates; GPCR, G protein-coupled receptor; MD, molecular dynamics; TM, transmembrane.
‡Present address: Beckman Institute for Advanced Science and Technology, University of
Illinois at Urbana–Champaign, Urbana, IL 61801.
§To whom correspondence should be addressed. E-mail: wag@wag.caltech.edu.
© 2006 by The National Academy of Sciences of the USA
4882–4887  PNAS  March 28, 2006  vol. 103  no. 13 www.pnas.orgcgidoi10.1073pnas.0511329103
onds (rigid motions) (10). We find results that are consistent with
most of these observations.
Results and Discussion: Changes in the Receptor Conformation
During Dynamics
Apo-2AR Simulations. Comparing the initial structure from the
MembStruk–HierDock predictions of apo-2AR (similar to Fig. 2
Left) to the structure after 4 ns of MD simulation in the presence
of a full membrane and water, we see some changes in the
conformation of the protein, some helices tilting closer to each
other, as discussed below, while the loops move substantially. Thus,
matching the C atoms of the TM helices of the apo-2AR
structure after 4 ns to the original structure for the two sets of MD
simulations, gives coordinate root mean square [RMS deviation in
 carbon coordinates (CRMS)] differences of 2.4 Å. In compar-
ison, the CRMS for the loops is 6.0 Å and 5.4 Å as expected
because these loops are fluxional.
Examining the two apo-2AR structures over the period of 6 ns,
we notice some conformations more suitable for binding agonist
[orientation of the OH group of Ser-207 (TM5) toward where the
catechol OH of the ligand would be], whereas others are not
[orientation of theOHgroup of Ser-207 (TM5) pointing toward the
OH group of Ser-165 (TM4)]. Comparing the two structures with
each other after 4 ns with each other, we find a CRMS difference
of 3.3 Å for the helical regions and 5.0 Å for the loops (due only to
their different initial velocities, before the MD), indicating the
flexibility of the system.
Butoxamine-2AR Simulations.With butoxamine-2AR we observe
less motion in the ligand and the helices compared with apo-2AR
(or epi-2AR), indicating a more rigid structure. Matching the
protein structure after 4 ns to the original butoxamine-2AR
structure gives a CRMS change of 2.1 Å for the helices and 5.9 Å
for the loops. Comparing the butoxamine molecules after 4 ns, we
find a RMS difference of 0.3 Å.
Epinephrine-2AR Simulations.Comparing the initial structure from
the MembStruk-HierDock predictions of epinephrine-2AR (the
left half of Fig. 2) to the structure after 4 ns of MD simulation in
the presence of a full membrane and water, we see some significant
changes in the conformation of the protein with an upward move-
ment of the epinephrine by1.2Åbut not out of the docking cavity.
Some helices tilt to become closer to each other, as discussed below.
Matching the protein structure after 4 ns to the original structure,
the CRMS difference is 2.3 Å. This finding shows that the
important structural elements of the predicted structure are main-
tained in the simulation.
However, more significant changes occur in the intracellular (IC)
and extracellular (EC) loops. These undergo large deformations, as
can be seen in Fig. 2. The CRMS differences in these loops range
from 3 Å to 5 Å.
Thus comparing the ligand–protein structures for agonist and
antagonist, we see that binding of the antagonist leads to a more
rigid structure. This increased rigidity may play a role in the
mechanism by which an antagonist prevents activation.
Dynamics of Water Through the 7TM Barrel.Fig. 3a shows the packing
of water in the apo-2AR-membrane complex at the start of the
MD, whereas Fig. 3b shows the structure for the apo-2AR after
3 ns of MD. This shows the formation of a water channel through
the central axis of the protein (the TM3, -4, -5, -6 barrel). However,
only 1 or 2 water molecules are observed to move through the
channel.
Some water channeling, but much less, is observed for epineph-
rine-2AR (Fig. 3c), whereas no water channel was found for
butoxamine-2AR (Fig. 3d). This procedure indicates a more rigid
structure for the antagonist than for the agonist and an even less
rigid structure for apo-2AR.
Fig. 1. Ligands used to study binding to the 2-adrenergic receptor. Epi-
nephrine is an endogenous ligand (agonist), whereas butoxamine is an an-
tagonist specific for 2AR.
Fig. 2. The structure of epinephrine-2AR at the start (Left) and after 4 ns of
MD simulations (Right). (a) Orthogonal top view. (b) Side view. The figure
shows that the tilts in helices 3 and 4 increase by an additional 6° and 7° with
respect to the surface normal of the lipid bilayer. The protein is shown in a
cartoon, and the epinephrine is shown as Van der Waals spheres. The program
VMD was used for visualization (15).
Fig. 3. The structure of the water for the initial structure (a) and after 3 ns
of MD simulations for apo-2AR (b), epinephrine-2AR (c), and butoxamine-
2AR (d). The protein and bilayer are omitted for clarity. The protein is located
in the center of each figure.
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We also observed water entering the conserved Asn-51 (TM1)–
Asp-79 (TM2)–Asn-322 (TM7) hydrogen bond network in theMD
run for apo-2AR and for epinephrine-2AR, but not for butox-
amine-2AR.
Role of Water in Mediating the Dynamics of the Interhelical Hydrogen
Bonds and Ligand–Protein Hydrogen Bonds. The MembStruk–
HierDock predictions contained no explicit solvent. Thus, the
explicit water simulations allow us to determine whether explicit
water plays an important role. Fig. 4b shows that indeed explicit
water mediates the hydrogen bond between Ser-204 (TM5) and
the catechol OH-group of epinephrine at some time steps during
the MD simulations. The first part of the hydrogen bond has a
length of 2.99 Å [from epinephrine to the water molecule,
measured with VMD (15)], and the second part has a length of
2.75 Å [from the water molecule to Ser-204 (TM5)].
At other times TM5 is oriented to form hydrogen bonds to TM4;
for example, Fig. 4a shows that at 172 ps a hydrogen bond is formed
between Ser-165 on helix 4 and Ser-207 on helix 5, which has a
length of 2.81 Å. We consider that the interhelical hydrogen bonds
between serines of helices 4 and 5 represent the inactive state before
binding of agonist. Binding of the epinephrine competes for some
of these same serines of helix 5. Hence, as the agonist enters the
binding pocket, helix 5 must rotate counterclockwise to make the
hydrogen bondwith the catechol groups. Indeed, during theMDwe
see just some changes with the TM5 orienting more toward TM4
when the ligand moves away (to allow the explicit water to enter),
and then the TM5 orients toward the ligand as it moves back (with
extra water).
We believe that this and other associated motions might play
a role in activation. Indeed, a two-state binding model leading to
activation has been proposed by several authors (7, 13). In
contrast, we saw little rotation in helix 5 for the antagonist
complex and only small f luctuations for the apoprotein.
Thus, the observation of water-mediated hydrogen bonds be-
tween helices or between the helix and epinephrine can play an
important role in activation, making explicit water calculations an
important final step in optimizing the predicted structure. Similarly,
such explicit water is likely quite important in determining absolute
bonding energies.
Quantitative Analysis of Helical Motion in MD Simulations. In this
section we examine the dynamic nature of the nonbond distances
to epinephrine from those residues known from experiment to be
involved in activation (13). This analysis may allow us to understand
the initial events leading to activation of 2AR. The residues for
which the distances have been measured experimentally are listed
in Table 1. The residues in this table are labeled according to
National Center for Biotechnology Information numbering. The
residues of interest are Asp-113, Ser-165, Ser-203, Ser-207, and
Asn-293 for epinephrine-2AR, and Asp-113, Hsd-172, Trp-286,
and Ile-294 for butoxamine-2AR. Of course, other residues not
listed here also interact with the ligand.
For hydrogen bonds we report the distance between the hydro-
gen bond acceptor and the hydrogen atom of the donor. For salt
bridges we report the closer distance between an oxygen of the
carboxylate group and the nitrogen of the protonated amine. For
hydrophobic interactions we report the distance between a carbon
atom to the closest hydrogen of the hydrophobic part of the other
molecule.
The butoxamine–helix interactions are somewhat similar with
those for epinephrine–helix, but butoxamine has fewer hydroxyl
groups (see Fig. 1) and fewer hydrogen bonds, and is likely to have
more hydrophobic interactions than for epinephrine. Fig. 5 shows
the variation with time of nonbond distances between the ligands
epinephrine (Upper) and butoxamine (Lower) and the residues of
interest. These figures show that the salt bridge between the
Asp-113 (TM3) and the protonated amine is preserved throughout
the dynamics for both ligands (arrows 1 and 2 in Fig. 5), leading to
an average length of 2.8 Å for epinephrine-2AR and 3.0 Å for
butoxamine-2AR. On the other hand, the ligand–protein hydro-
gen bonds fluctuate during the MD. The hydrogen bond between
the metacatechol hydroxyl group of epinephrine with Ser-203
Fig. 4. Structural elements in epinephrine-2AR. (a) The hydrogen bond
between Ser-165 (helix 4) and Ser-207 (helix 5), with a length of 2.81 Å. (b) The
water-mediated hydrogen bond between the para-catechol OH of epineph-
rine and Ser-204 (helix 5). This mediated hydrogen bond has lengths of 2.99 Å
(from epinephrine to water) and 2.75 Å (from water to Ser-204). In both
figures the hydrogen bonds are depicted by a dotted yellow line, the protein
is shown as a ribbon, and the serine residues of interest, the water, and
epinephrine are shown as a stick model. Water and the bilayer have been
omitted for clarity. The program VMD was used for visualization (15).
Table 1. The residues of the 2AR that play a role in binding the
ligands epinephrine and butoxamine (listed by helix)
Ligand Helix 3 Helix 4 Helix 5 Helix 6
Epinephrine Asp-113 Ser-165 Ile-201 Phe-290
Val-117 Ile-169 Ser-203 Asn-293
Ser-204
Ser-207
Butoxamine Asp-113 Ile-169 Ser-203 Trp-286
Cys-116 Hsd-172 Asn-293
Ile-294
Val-297
The residues in this table are labeled according to National Center for
Biotechnology Information numbering.
Fig. 5. Variation of nonbond distances with time for several residues in the
2AR. (Upper) Epinephrine-2AR. (Lower) Butoxamine-2AR. The different
residues are listed in the legends to the right. For Ser-203, we report the
distances to both two OH groups of the catechol moiety of epinephrine. The
arrows indicate specific events, which are discussed in the text.
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(TM5) is maintained as a direct hydrogen bond for 0.8 ns (the
breakage is indicated by arrow 3 in Fig. 5) and as a water-mediated
hydrogen bond for another 0.8 ns (the breakage is indicated by
arrow 4 in Fig. 5). The hydrogen bond between Asn-293 and the
-hydroxyl group on the alkyl chain of epinephrine is lost near the
beginning of the simulation (arrow 3 in Fig. 5) but forms again after
2 ns (arrow 5 in Fig. 5). Most other hydrogen bonds between TM4
(Ser-165) and TM5 (Ser-204) are lost almost immediately (arrow 3
in Fig. 5).
During the MD simulations, butoxamine continues to exhibit
hydrophobic interactions with His-172 (TM4) and Trp-286 (TM5)
and Ile-294 (TM6). Fig. 5 shows that these interactions remain tight
through the entire MD run. It is found that the hydrophobic
interactions with Val-119, Ile-169, and Phe-290 remain rather
constant (4.5 Å) throughout the MD run.
The nonbond distances between residues on different helices
were also analyzed to understand how the dynamics in lipid and
water affect the interhelical distances. We find that during the
dynamics the Ser-207 (TM5) breaks its hydrogen bond with epi-
nephrine forming instead a hydrogen bond with Ser-165 (TM4) as
seen in Fig. 4. This is associated with the rotation of TM5 men-
tioned above.
Based on visual inspection of the simulation trajectories, we
chose to follow the dynamics of certain residues explicitly. The
distances between the residues are calculated in the same way as
with the lengths of the nonbond interactions between ligand and
residue. For the apoprotein and epinephrine–protein simulations,
we examined the distances of three pairs Thr-164 to Ser-203,
Thr-164 to Ser-207, and Ser-165 to Ser-207 (all between TM4 and
-5). Except for the pair Ser-165 to Ser-207, these interactions are not
found in the butoxamine simulation. On the other hand, in the
butoxamine simulation the pair Asp-113 to Asn-293 (from helix 3
to 6) seems interesting and was investigated. These distances are
shown in Fig. 6.
In both the apoprotein and butoxamine–protein simulation,
these hydrogen bonds loosen during the MD. However, for epi-
nephrine-2AR the hydrogen bond between Ser-165 and Ser-207
is conserved for almost 3 ns. It then loosens, but at the same time
the distance from Thr-164 (TM4) to both Ser-203 (TM5) and
Ser-207 (TM5) tightens considerably (arrow 1 in Fig. 6). For the
next 3 ns the distances remain constant, indicating strong interheli-
cal interaction (arrow 2 in Fig. 6). At the end of the simulation the
hydrogen bond between Thr-164 and Ser-203 loosens, but the
hydrogen bond between Thr-164 and Ser-207 and Ser-165 and
Ser-207 tightens, indicating an increase in strength (arrow 3 in Fig.
6). The presence of these interhelical hydrogen bonds in the agonist
complex and their absence in the apoprotein and antagonist
complex suggest that these interactions induced by the agonist
might be important for receptor activation. Recent experiments on
rhodopsin (the onlyGPCR forwhich a crystal structure is available)
also showed the importance of interhelical hydrogen bonding as a
step in the protein activation (16).
Fig. 7 shows the helical conformation of the protein for helices
3–6 for the initial (black) and final (t 6 ns; white) conformations.
The side view (Fig. 7a) shows that helices 3 and 6 have moved
downwards (5 Å), and that the intracellular ends of helices 4 and
5 have moved in different directions. The top view (Fig. 7b)
illustrates the observationmade above that the extracellular ends of
helices 3 and 6 move apart. This is an important observation,
because it is known that the G protein is coupled to the highly
conserved DRY-motif (an ASP-ARG-TYR sequence) located at
the end of helix 3. The DRY-motif is believed to play an important
role in protein activation (17). Thus, the motions observed with
respect to helix 3 provide a strong indication that such motions are
involved upon in protein activation.
In comparing structures, we have calculated theRMS distance of
the helical backbone (CRMS) in two ways. The absolute CRMS
gives information on the correlation of a protein structure through-
out time with respect to the initial structure to provide some idea
about the accuracy of the original structure. The relative CRMS
gives insight in the dynamical correlation of two in time subsequent
structures equilibrated in membrane and water. Both types of
CRMS are shown in Fig. 8. The CRMS values of 1–2 Å for the
2AR structure show that the predicted structure is stable in lipid
bilayer. The relative CRMS slowly converges to a value of 0.6 Å,
indicating the range of dynamical fluctuation in the structure.
Conclusions
These analyses of the fully solvated structures with a complete
description of themembranemake it clear that the overall predicted
2AR structures are stable. The helices move somewhat with
respect to each other, but there are no large instabilities, and the
helical conformations are preserved. Although the structure pre-
dictions used only a small lipid barrel, we see only modest changes
Fig. 6. Interactions between residues residing on different helices for all four
simulations. (Upper) Lengths of these noncovalent bonds for the apoprotein
simulations. (Lower Left) Epinephrine simulation. The Thr-164 to Ser-203
interaction is shown in blue, the Thr-164 to Ser-207 interaction is in green, and
the Ser-165 to Ser-207 interaction is in red. Residues Thr-164 and Ser-165 are
on helix 4, and residues Ser-203 and Ser-207 are on helix 5. (Lower Right)
Interactions for the butoxamine simulation between Asp-113 on helix 3 and
Asn-293 on helix 6 (in blue) and Ser-165 on helix 4 and Ser-207 on helix 5 (in
green). The arrows indicate specific events, which are discussed in the text.
Fig. 7. Schematic representation of the change in helical configuration for
the helices surrounding the docking cavity (helices 3–6). (a) Side view. (b) Top
view. The initial configurations are shown in black (also the ligand epineph-
rine), and the final configurations are shown in white. The remainder of the
protein, as well as the bilayer and the water, is omitted for clarity. The
program VMD was used for visualization (15).
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from including the full membrane in the model. Thus, the CRMS
comparisons show that the conformations of the 2AR are stable
in the native bilayer-water environment. This finding validates the
MembStruk procedure, indicating that the MembStruk predicted
structures are reasonably accurate. The minor changes in the
ligand–protein interaction caused by the presence of water and lipid
indicate that including explicit water would have been useful in
docking the agonist to the receptor. The behavior of the interhelical
loops shows that these loops are very dynamic, as expected,
indicating that an ensemble of favorable loop structures should be
considered in the docking calculations.
Examination of the MD trajectory indicates that explicit
inclusion of water has some significant effects on ligand–residue
interactions and that these interactions change dynamically. The
strong salt bridge interactions between Asp-113 (TM3) and the
protonated amine of both epinephrine and butoxamine are
preserved in the dynamics, confirming the importance of this
interaction for the fast binding step (12) of the ligand, be it an
agonist or an antagonist. The hydrogen bonds between serines
on TM5 and epinephrine are slower to form, being water-
mediated and dynamic in nature. We observe here an interheli-
cal hydrogen bond between helices 4 and 5 that must break to
form the hydrogen bonds with the catechol group of epineph-
rine. This finding shows that the step of forming hydrogen bonds
with the catechol group is slow, involving a competition between
forming interhelical hydrogen bonds (the inactive state of the
receptor) and forming the hydrogen bonds with the agonist
epinephrine (the active state). Thus, the agonist binding and
activation involves at least two steps, as observed in the MD: the
protonated amine contact with Asp-113 (TM3) is made first
followed by rotation of helix 5 to make hydrogen bonds with the
catechol of epinephrine. These conclusions drawn from the MD
simulations are consistent with similar conclusions by other
researchers based on experiments (13, 16).
The motion of helices 3 and 6 downward (see Fig. 7) occurred
only with the agonist epinephrine bound and not with either the
antagonist bound protein or the apoprotein. The piston-like
movements of these helices could be involved in the activation
of the protein (10), and the motions we observe probably show
the beginning of these piston-like movements.
The changes in the interhelical hydrogen bonding between
helix 4 and 5 as the agonist is bound are most interesting. It
remains fairly stable throughout the simulation. In addition, the
occurrence of water-mediated hydrogen bonds shows that water
can play a critical role in ligand binding. The differences in the
simulations between the antagonist-protein, the agonist-protein,
and the apoprotein structure make it clear that just 6 ns of
simulations already show differences between agonist and an-
tagonist that can be compared with experiment. However, longer
simulations would certainly contribute to confirm the observed
behavior. Thus, we find that antagonist-protein simulations
differ substantially from the dynamics of the apoprotein and of
the agonist-2AR systems.
Computational Methods
The Structural Model. The initial 3D structure of the human 2AR
was obtained fromMembStruk predictions (3, 4, 7), whereas the
3D structures with the ligands epinephrine or butoxamine bound
to 2AR were obtained from HierDock predictions (5, 7). The
protonated amine of epinephrine forms a salt bridge with the
Asp-113 on TM3. The catechol hydroxyl groups form a hydrogen
bond network with Ser-203, Ser-204, and Ser-207 on TM5. The
-hydroxyl group in the alkyl chain of epinephrine hydrogen
bonds to Asn-293 on TM6. Epinephrine also has hydrophobic
interactions with Val-119 on TM3, Ile-169 on TM4, and Phe-290
on TM6.
The butoxamine antagonist, which is larger and more hydro-
phobic than epinephrine, interacts with such additional hydro-
phobic residues as Trp-109 on TM3 and Phe-289, Phe-290, and
Ile-294 on TM6. The oxygens on butoxamine were involved in
hydrogen-bonding interactions with Ser-203 and Ser-204, but
there was no interaction with Ser-207 on TM5. There was no
direct experimental validation for this binding site. However, the
HierDock predictions for several agonists and antagonists gave
reasonable relative binding energies (7), and these dynamics
studies show very little change in the ligand–protein complex
from the predicted binding site. Thus, we believe that the
predicted binding site for butoxamine is correct. We consider
both epinephrine and butoxamine to be protonated, at physio-
logical conditions.
The butoxamine antagonist, which is larger and more hydro-
phobic than epinephrine, interacts with such additional hydro-
phobic residues as Trp-109 on TM3 and Phe-289, Phe-290, and
Ile-294 on TM6. The oxygens on butoxamine were involved in
hydrogen-bonding interactions with Ser-203 and Ser-204, but
there was no interaction with Ser-207 on TM5.We consider both
epinephrine and butoxamine to be protonated, at the physio-
logical conditions.
To construct the periodic cell for the MD simulations, the
predicted structures of apo-2AR, epinephrine-2AR, and
butoxamine-2AR from ref. 7 were each independently em-
bedded in the center of a square periodic lipid bilayer con-
sisting of 200 dipalmitoyl phosphatidyl choline molecules and
solvated with 15,000 water molecules. The dimensions par-
allel to the membrane were 92 Å and 80 Å, and the diameter
of the protein barrel was 27 Å. The periodic cell measures 100
Å perpendicular to the membrane, and the thickness of the
membrane was 38 Å and the total thickness of the protein was
55 Å. To compensate for the net charge of the protein and
ligand, eight waters for the apoprotein or nine waters for the
ligand-bound protein were replaced by chloride ions to attain
a zero net charge for the entire system. The initial structure for
epinephrine-2AR is shown in Fig. 9. These systems contains
76,253 atoms (apoprotein-2AR), 76,278 atoms (epinephrine-
2AR), and 76,296 atoms (butoxamine-2AR).
We used the CHARMM22 force field parameters for the protein,
the TIP3 model for water (18, 19), and the CHARMM27 force field
parameters for the lipids (20). Because not all force field
parameters were available for epinephrine and butoxamine in
CHARMM, we derived these parameters from parameters already
Fig. 8. Backbone root mean square distances (CRMS) for several sets of
simulations. (Upper) The absolute CRMS (with respect to the first frame).
(Lower) The relative CRMS (with respect to the previous frame).
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present in the CHARMM force field for similar chemical groups.
These new parameters are reported in the supporting informa-
tion, which is published on the PNAS web site. Minimization of
both ligands in vacuum for these ligands led to bond lengths,
angles, and dihedrals similar to the quantum mechanical results
and the previous structures determined with DREIDING (21).
Gasteiger charges were used for these ligands (22).
Simulations Details. Four independent MD simulations, each 6 ns
long, were carried out by using the program NAMD 2.5 for all
minimization and MD runs (23, 24). Two of these simulations
considered only apo-2AR embedded in the bilayer and solvated
in the water (including the chloride ions to account for the net
charge). These two apoprotein simulations differ only by having
their initial velocities redefined (independent assignment of the
Gaussian distributions). The other two simulations were epi-
nephrine-2AR and butoxamine-2AR.
The process was first to minimize the water and lipid bilayer
while keeping the protein and ligand fixed. This was followed by
an all-atom conjugate gradient minimization of the entire system
for 20,000 steps. After this minimization, we carried out 5 ps of
MD simulations for equilibration (not used for analysis) using
1-fs time steps, followed by 6 ns of MD simulations with the same
time step size. Langevin dynamics was used for temperature
control with the thermostat set at 310 K. The Nose´–Hoover
Langevin piston pressure control was used to control f luctua-
tions in the barostat, which was set at a pressure of 1 bar (1 bar
100 kPa). Here the periodic cell was constrained to remain
orthorhombic, but the cell parameters were allowed to vary. A
dielectric constant of 1 was used for the electrostatic interac-
tions, which were calculated by using the particle mesh Ewald
method (18, 25). The grid in the x, y, and z directions used for
the particle mesh Ewald method was set at 96, 80, and 108 points,
respectively. The van der Waals interactions were described by
using a Lennard–Jones function multiplied by a cubic spline
switching function starting at 8 Å and stopping at 12 Å. The cut
off radius for including atoms in the nearest-neighbor list was
13.5 Å. All 1–2 and 1–3 interactions were excluded, and 1–4
interactions were scaled by multiplication with a predefined
factor. The bonded interactions were calculated every time step,
the nonbonded interactions were calculated every other time
step, and the electrostatic interactions were calculated every
fourth time step. The nearest-neighbor list was updated every 20
time steps. Every 10 ps a snapshot was written to the trajectory
file for subsequent analysis.
The hardware configuration used for these simulations was a
Linux-based Beowulf cluster running on RedHat Linux 7.3 at
either the Materials Process and Simulation Center at the
California Institute of Technology or the Department of Bio-
medical Engineering at the Technische Universiteit Eindhoven.
Each central processing unit in either of the two clusters was an
Intel P4 2.2-GHz processor with 1 GB of memory. For each case
(consisting of minimization and dynamics), a total of 5,800
processor hours was needed.
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Fig. 9. A schematic view of the epinephrine-2AR–lipid bilayer water com-
plex. (a) A bird’s-eye perspective of the complex with all waters omitted.
Visible are the protein (red, indicated by the arrow) and the lipid bilayer
(green for carbons, and white for head groups). The epinephrine is not visible,
because it is in the pocket inside the protein. (b) An orthogonal side view of
the complex with water in blue. The protein is not visible, because it is inside
the membrane and the water. The width of the periodic cell is 92 Å, and the
height is 100 Å.
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